Nasdaq
$211.77▼ 1.11%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $13.30BShares out 62.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
62- 10.9Pre-market26.10.09 22:028-KKey event#●●●
Jazz Pharmaceuticals plc
Samantha Pearce, Executive Vice President and Chief Commercial Officer of Jazz Pharmaceuticals, notified the company of her intent to retire on October 6, 2026. She will step down upon the appointment of a successor or by June 30, 2027, and the company has initiated a formal search for her replacement.…more
$211.77-1.11%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.8After-hours26.10.09 05:04144Ownership
Jazz Pharmaceuticals plc
Anne O'Riordan, an executive at Jazz Pharmaceuticals plc, has filed an SEC Form 144 to report a plan for the sale of company shares. This is a standard disclosure regarding an insider's stock disposal plan.…more
$211.77-1.11%vs prev closeView filingShare - 10.7After-hours26.10.08 06:444Ownership
Jazz Pharmaceuticals plc
Renee D. Gala, an executive at Jazz Pharmaceuticals, filed an SEC Form 4 on October 7, 2026, reporting changes in beneficial ownership of company securities as of October 6, 2026. This filing serves as a standard disclosure of insider equity transactions.…more
$211.77-1.11%vs prev closeView filingShare
61 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 1d agoRegular26.10.23 23:20#●●●#●●●#●●●
Jazz Pharmaceuticals Presents Phase 3 Data for Ziihera in Gastric Cancer…more
Jazz Pharmaceuticals presented final overall survival data from its Phase 3 HERIZON-GEA-01 trial for Ziihera in treating HER2-positive gastroesophageal adenocarcinoma at ESMO 2026. These results highlight the drug's potential as a first-line treatment, marking a significant step in its clinical development program.…more
$211.77-1.11%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.22Overnight26.09.22 11:00
●●●●●●●● ●●●●● ●●●●●●
Iambic Therapeutics, an AI-driven drug discovery company backed by Nvidia, has filed for an initial public offering on the Nasdaq. While the company has seen revenue growth, it reported widening net losses and plans to use IPO proceeds to fund clinical trials for its cancer drug candidates.…more
$211.77-1.11%vs prev closeShareBenzinga - 8.31Pre-market26.08.31 19:04
●●●●●●●● ●●●●● ●●●●●●
Jazz Pharmaceuticals announced that its drug candidate Ziihera demonstrated statistically significant improvements in overall survival compared to standard treatment in a Phase 3 trial for HER2-positive gastroesophageal adenocarcinoma. These results establish Ziihera as a potential new benchmark for first-line treatment in this aggressive cancer indication.…more
$211.77-1.11%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report